All Cancer articles – Page 15
-
NewsNew CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
-
NewsUSC partners with Autobahn Labs to accelerate drug discovery
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
-
ArticleBiotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
-
NewsCarbonic anhydrase inhibitors protect against tau protein build-up
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
-
NewsINPP4B exerts its tumour-promoting effects via lysosomes
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
-
NewsNew AI model may enable more targeted prostate cancer treatment
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
-
Newsp53's role in ulcerative colitis and its progression to cancer
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
-
NewsComputational pipeline for personalised cancer vaccine design
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
-
News
How chronic stress hastens the progression of colorectal cancer
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
-
ArticleCombining precision bispecific antibodies with targeted radiotherapy
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander ...
-
News
Developing the world’s first ovarian cancer prevention vaccine
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
-
NewsKRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
-
News
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
-
Article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional ...
-
NewsAnti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
-
NewsLargest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
-
ArticleInitial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy ...
-
News
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
-
NewsBCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
-
NewsNew network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.